“This latest health care price growth report indicates that spending on pricey prescription medications shows no sign of slowing down. When compared to other health care services, it is clear that high cost treatments continue to top the charts as a serious threat to the sustainability of our health care system and beyond.”

“The approval of Repatha is another example of a breakthrough medication with a too high price tag. With several game-changing medications in the pipeline, we need to address the underlying issue of how these prices are set from the start before they hit the market.”

“These numbers paint a troubling picture for the future of the American economy. The dramatic rise in prescription drug spending proves that it is more important than ever to advance a solution to monopolistic drug pricing. We cannot afford to continue on this unsustainable path.”

“Breakthrough treatments such as Praluent hold tremendous medical promise for certain patients, but it’s price tag makes us question how long the health system can sustain these costs for patients managing chronic conditions over several years.”

FOR IMMEDIATE RELEASE Contact: Kara Batt (571) 239-6547 [email protected] #### May 20, 2015 — UAW Retiree Medical Benefits Trust (the “Trust”), the largest non-governmental payor of retiree health care benefits in the United States, has joined the Campaign for Sustainable Rx Pricing (CSRxP), a broad-based coalition working for solutions to skyrocketing prescription drug prices. “As […]

May 13, 2015 New Drug Report Reveals Drug Costs Top $50,000/year for Over Half a Million Americans Reaction from National Coalition on Health Care President and CEO John Rother on key findings from Express Scripts “Super Spending: U.S. Trends in High-Cost Medication Use.”  “The Express Scripts “Super Spending: U.S. Trends in High-Cost Medication Use” report released today […]